U.S. FDA Approves Expanded Label for Astellas’ IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy

Posted on by

IZERVAY dosing approved beyond 12 months TOKYO, Feb. 12, 2025 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced the U.S. Food and Drug Administration (FDA) approved expanded U.S. Prescribing information for IZERVAY™…